Media & Funding

Welcome to UCB's media room. This section offers resources for journalists, editors and other media professionals.

^PrBIMZELX^®

Now Approved in Canada for the Treatment of Moderate to Severe Hidradenitis Suppurativa (HS)

UCB Canada Expands FASTRAX to Thunder Bay

Enhancing Axial Spondyloarthritis (axSpA) Patient Care in Northern Ontario

Enhanced Access to gMG Treatments:

UCB Canada Secures pCPA Agreements for ZILBRYSQ^® and RYSTIGGO^®

^PrRYSTIGGO^®

Now Approved for Adults with Generalized Myasthenia Gravis (gMG) in Canada

02/03/2024

ZILBRYSQ^® (zilucoplan injection)

Now Approved for Adults with Generalized Myasthenia Gravis (gMG) in Canada

07/16/2024

BIMZELX^® (bimekizumab)

Now Approved for Adults with Active Psoriatic Arthritis and for Adults with Axial Spondyloarthritis

If you are a member of the media and require further information about UCB Canada Inc. or its products, please contact: mediacanada@ucb.com.